Business Context and Reporting Period
This Form 8-K Current Report was filed by OncoCyte Corporation (noted as Insight Molecular Diagnostics Inc. in metadata) on February 7, 2019, with the report date covering events through February 12, 2019. The registrant is an emerging growth company incorporated in California. The filing primarily documents the entry into a material definitive agreement for an underwritten public offering of common stock.
Key Financial Metrics and Transaction Details
The filing details a capital raise transaction rather than standard operating financial metrics. Key figures include:
- Shares Issued: 9,333,334 shares of common stock in the primary offering.
- Over-Allotment Option: Underwriters exercised an option to purchase an additional 1,400,000 shares.
- Offering Price: $3.75 per share to the public.
- Price to Company: $3.49312 per share.
- Net Proceeds: Approximately $37.0 million after deducting underwriting discounts, commissions, and estimated offering expenses.
- Closing Date: February 12, 2019.
The filing text does not provide clear values for revenue, profit, cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the significant increase in equity capital and cash liquidity resulting from the closing of the public offering. The company transitioned from a pre-offering state to having secured approximately $37.0 million in net proceeds. No comparative period financial data is provided in this specific filing to quantify changes in operating performance.
Guidance, Outlook, and Risks
The filing does not contain specific forward-looking guidance, revenue outlook, or management commentary regarding future operational performance. The document notes that the Purchase Agreement contains customary representations, warranties, and indemnification obligations. It explicitly states that the description of the agreement is qualified by reference to the full agreement filed as an exhibit. No specific risks or contingencies are detailed in the body of this report beyond standard legal disclaimers regarding the agreement terms.
Investor Verification Checklist
- Verify the final number of shares issued including the full exercise of the 1,400,000 share over-allotment option.
- Confirm the exact net proceeds received after all closing expenses, as the $37.0 million figure is an estimate.
- Review the full Purchase Agreement (Exhibit 1.1) for specific covenants, lock-up periods, or use-of-proceeds restrictions.
- Check subsequent filings for the actual impact of these proceeds on the company's cash position and balance sheet.
- Confirm the company's status as an emerging growth company and any election regarding extended transition periods for accounting standards.